Sangamo BioSciences Announces Fourth Quarter And Full Year 2012 Conference
Call And Webcast
RICHMOND, Calif., Jan. 30, 2013
RICHMOND, Calif., Jan. 30, 2013 /PRNewswire/ -- Sangamo BioSciences, Inc.
(Nasdaq: SGMO) today announced that the company will release its fourth
quarter and full year 2012 financial results on Wednesday, February 6, 2013,
after the market closes. The press release will be followed by a conference
call at 5:00 p.m. ET, which will be open to the public via telephone and
webcast. During the conference call, the company will review the financial
results and discuss other business matters.
The conference call dial-in numbers are 877-377-7553 for domestic callers and
678-894-3968 for international callers. The passcode for the call is
92659211. Participants may access the live webcast via a link on the Sangamo
BioSciences website in the Investors section under Events and Presentations.
For those unable to listen in at the designated time, a conference call replay
will be available for one week following the conference call, from
approximately 8:00 p.m. ET on February 6, 2013 to 11:59 p.m. ET on February
13, 2013. The conference call replay numbers for domestic and international
callers are 855-859-2056 and 404-537-3406, respectively. The conference ID
number for the replay is 92659211.
Sangamo BioSciences, Inc. is focused on research and development of novel
DNA-binding proteins for therapeutic gene regulation and genome editing. The
Company has ongoing Phase 2 clinical trials to evaluate the safety and
efficacy of a novel ZFP Therapeutic^® for the treatment of HIV/AIDS. Sangamo's
other therapeutic programs are focused on monogenic diseases, including
hemophilia, Huntington's disease and hemoglobinopathies such as sickle cell
anemia and beta-thalassemia. Sangamo's core competencies enable the
engineering of a class of DNA-binding proteins known as zinc finger
DNA-binding proteins (ZFPs). Engineering of ZFPs that recognize a specific
DNA sequence enables the creation of sequence-specific ZFP Nucleases (ZFNs)
for gene modification and ZFP transcription factors (ZFP TFs) that can control
gene expression and, consequently, cell function. Sangamo has entered into a
strategic collaboration with Shire AG to develop therapeutics for hemophilia,
Huntington's disease and other monogenic diseases, and it has also established
strategic partnerships with companies in non-therapeutic applications of its
technology including Dow AgroSciences and Sigma-Aldrich Corporation. For more
information about Sangamo, visit the company's website at www.sangamo.com
ZFP Therapeutic^® is a registered trademark of Sangamo BioSciences, Inc.
SOURCE Sangamo BioSciences, Inc.
Contact: Elizabeth Wolffe, Ph.D., Sangamo BioSciences, Inc., +1-510-970-6000,
Press spacebar to pause and continue. Press esc to stop.